甲状腺癌发生颈淋巴结转移与疾病复发和患者预后密切相关。准确判断淋巴结转移对肿瘤分期及治疗至关重要,可有效改善患者预后。然而,术前发现颈淋巴结转移是甲状腺癌患者个体化诊治的重点和难点。目前,临床上常使用细针穿刺洗脱液甲状腺球蛋白检测在术前评估分化型甲状腺癌颈淋巴结转移情况,其诊断效能较高。对肿瘤标记物及新兴生物标记物的不断探索与应用,为甲状腺癌术前淋巴结转移诊断研究提供了崭新的视角。液体活检作为一种新型无创的检测技术,获取样本方便,在早期诊断甲状腺癌颈淋巴结转移方面具有广阔的临床应用前景。此外,液体活检生物标志物的分析与应用,将有助于临床诊疗策略的制定,为甲状腺癌患者的早期精准治疗提供可能。本文围绕甲状腺癌颈淋巴结转移相关分子标志物的研究进展进行综述。 Cervical lymph node metastasis in thyroid cancer is closely related to the disease recurrence and prognosis of patients. Accurate judgment of lymph node metastasis is vital for tumor stage and treatment in patients with thyroid cancer, which can effectively improve the prognosis of patients. However, preoperative detection of cervical lymph node metastasis is the key points and difficulties in individualized treatment of thyroid cancer. Currently, fine needle aspiration washout fluid thyroglobulin is often used to assess cervical lymph node metastasis of differentiated thyroid cancer preoperatively, and it has a higher diagnostic efficacy. The continuous exploration and application of tumor markers and emerging biomarkers have provided new perspectives for the preoperative diagnosis of lymph node metastasis in thyroid cancer. As a new non-invasive detection technique, liquid biopsy is convenient to obtain samples and has broad clinical application in early diagnosis of cervical lymph node metastasis of thyroid cancer. In addition, the analysis and application of liquid biopsy biomarkers will help the development of clinical diagnosis and treatment strategies, and provide the possibility of early precision therapy for thyroid cancer patients. This review summarizes current research surrounding the molecular markers related to cervical lymph node metastasis of thyroid cancer.
Abstract
Cervical lymph node metastasis in thyroid cancer is closely related to the disease recurrence and prognosis of patients. Accurate judgment of lymph node metastasis is vital for tumor stage and treatment in patients with thyroid cancer, which can effectively improve the prognosis of patients. However, preoperative detection of cervical lymph node metastasis is the key points and difficulties in individualized treatment of thyroid cancer. Currently, fine needle aspiration washout fluid thyroglobulin is often used to assess cervical lymph node metastasis of differentiated thyroid cancer preoperatively, and it has a higher diagnostic efficacy. The continuous exploration and application of tumor markers and emerging biomarkers have provided new perspectives for the preoperative diagnosis of lymph node metastasis in thyroid cancer. As a new non-invasive detection technique, liquid biopsy is convenient to obtain samples and has broad clinical application in early diagnosis of cervical lymph node metastasis of thyroid cancer. In addition, the analysis and application of liquid biopsy biomarkers will help the development of clinical diagnosis and treatment strategies, and provide the possibility of early precision therapy for thyroid cancer patients. This review summarizes current research surrounding the molecular markers related to cervical lymph node metastasis of thyroid cancer.